This episode of Chromatography Life takes a closer look at synthetic peptide drugs - one of the most compelling frontiers in biopharmaceutical analysis.

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...

More Americans are turning to drugs like Ozempic and Wegovy to shed pounds. but for many, the transformation doesn't stop ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

Renaissance Investment Management, an investment management company, released its Q1 2025 “Small Cap Growth Strategy” ...

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis ...

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...

At HLTH Europe 2025, experts warned that stigma, cost barriers, and lack of support are hindering the wider use of GLP-1s in ...